Coya Therapeutics, Inc. (COYA) analyst actions
Rating and price-target actions on COYA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the COYA overview →
5 measured COYA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients | Press release | +3.50% | -0.58% | |
| Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia | Press release | +1.08% | +1.62% | |
| Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia | Press release | +0.79% | -4.39% | |
| Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) | Press release | -0.98% | -7.79% | |
| Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease | Press release | +0.99% | +11.86% |
Keep exploring
More COYA: earnings → · SEC filings → · COYA overview →